Tags

Type your tag names separated by a space and hit enter

The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Hepatogastroenterology. 2013 Nov-Dec; 60(128):2034-8.H

Abstract

BACKGROUND/AIMS

Although the incidence of hepatocellular carcinoma (HCC) has been shown to be reduced after pegylated glycol-interferon plus ribavirin (Peg-IFN/RBV) therapy in patients with chronic hepatitis C, the risk factors for the development of HCC are not fully understood. The aim of this study was to clarify the incidence and the risk factors for the development of HCC after Peg-IFN/RBV therapy in patients with chronic hepatitis C.

METHODOLOGY

A total of 474 patients with chronic hepatitis C who received Peg-IFN/RBV therapy between December 2004 and August 2010 were enrolled and followed in a multicenter trial. The patients were assessed for HCC by either ultrasound or computed tomography every 6 months. The incidence and risk factors for the development of HCC were identified.

RESULTS

Of the 474 patients, 23 developed HCC during a median follow-up of 4 years and 8 months (range 1-6 years and 3 months) after completion of Peg-IFN/RBV therapy. According to a univariate analysis, higher age, low platelet counts, a low level of serum albumin, a high level of alpha-fetoprotein (AFP) and a sustained viral response (SVR) to Peg-IFN/RBV therapy were independent factors associated with the occurrence of HCC. The multivariate analysis using the Cox proportional hazard model revealed the risk factors for HCC were the platelet count, AFP level and the outcome of Peg-IFN/RBV therapy.

CONCLUSIONS

To reduce the incidence of HCC in chronic hepatitis C, attainment of a sustained response rate is an essential issue. For patients with low platelet counts and/or a high AFP level, strict surveillance should be continued even after eradication of HCV because the risk of HCC was found to be higher for these patients.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

24719946

Citation

Dohmen, Kazufumi, et al. "The Incidence and Risk Factors for the Development of Hepatocellular Carcinoma After Peginterferon Plus Ribavirin Therapy for Chronic Hepatitis C." Hepato-gastroenterology, vol. 60, no. 128, 2013, pp. 2034-8.
Dohmen K, Kawano A, Takahashi K, et al. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. Hepatogastroenterology. 2013;60(128):2034-8.
Dohmen, K., Kawano, A., Takahashi, K., Shigematsu, H., Tanaka, H., Haruno, M., Yanagita, K., Ichiki, Y., Mori, T., Hayashida, K., Shimoda, S., Ishibashi, H., & Nomura, H. (2013). The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. Hepato-gastroenterology, 60(128), 2034-8.
Dohmen K, et al. The Incidence and Risk Factors for the Development of Hepatocellular Carcinoma After Peginterferon Plus Ribavirin Therapy for Chronic Hepatitis C. Hepatogastroenterology. 2013;60(128):2034-8. PubMed PMID: 24719946.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. AU - Dohmen,Kazufumi, AU - Kawano,Akira, AU - Takahashi,Kazuhiro, AU - Shigematsu,Hirohisa, AU - Tanaka,Hirofumi, AU - Haruno,Masatora, AU - Yanagita,Kimihoko, AU - Ichiki,Yasunori, AU - Mori,Tetsu, AU - Hayashida,Kazuhiro, AU - Shimoda,Shinji, AU - Ishibashi,Hiromi, AU - Nomura,Hideyuki, PY - 2014/4/11/entrez PY - 2014/4/11/pubmed PY - 2014/5/16/medline SP - 2034 EP - 8 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 60 IS - 128 N2 - BACKGROUND/AIMS: Although the incidence of hepatocellular carcinoma (HCC) has been shown to be reduced after pegylated glycol-interferon plus ribavirin (Peg-IFN/RBV) therapy in patients with chronic hepatitis C, the risk factors for the development of HCC are not fully understood. The aim of this study was to clarify the incidence and the risk factors for the development of HCC after Peg-IFN/RBV therapy in patients with chronic hepatitis C. METHODOLOGY: A total of 474 patients with chronic hepatitis C who received Peg-IFN/RBV therapy between December 2004 and August 2010 were enrolled and followed in a multicenter trial. The patients were assessed for HCC by either ultrasound or computed tomography every 6 months. The incidence and risk factors for the development of HCC were identified. RESULTS: Of the 474 patients, 23 developed HCC during a median follow-up of 4 years and 8 months (range 1-6 years and 3 months) after completion of Peg-IFN/RBV therapy. According to a univariate analysis, higher age, low platelet counts, a low level of serum albumin, a high level of alpha-fetoprotein (AFP) and a sustained viral response (SVR) to Peg-IFN/RBV therapy were independent factors associated with the occurrence of HCC. The multivariate analysis using the Cox proportional hazard model revealed the risk factors for HCC were the platelet count, AFP level and the outcome of Peg-IFN/RBV therapy. CONCLUSIONS: To reduce the incidence of HCC in chronic hepatitis C, attainment of a sustained response rate is an essential issue. For patients with low platelet counts and/or a high AFP level, strict surveillance should be continued even after eradication of HCV because the risk of HCC was found to be higher for these patients. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/24719946/The_incidence_and_risk_factors_for_the_development_of_hepatocellular_carcinoma_after_peginterferon_plus_ribavirin_therapy_for_chronic_hepatitis_C_ L2 - http://www.diseaseinfosearch.org/result/3332 DB - PRIME DP - Unbound Medicine ER -